4.8 Article

A Nuclear-Targeted AIE Photosensitizer for Enzyme Inhibition and Photosensitization in Cancer Cell Ablation

Journal

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 61, Issue 15, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202114600

Keywords

Nuclear Targeting; Histone Deacetylase Inhibition; Photosensitizer; Nucleic Acid Damage; Telomerase Inhibition

Funding

  1. National University of Singapore [R279-000-482-133]
  2. Fundamental Research Funds for the Central Universities (SYSU)
  3. National Natural Science Foundation of China [91953117, 21837006]
  4. Ministry of Education of China [IRT-17R111]
  5. 973 Program [2015CB856301]
  6. Guangdong Basic and Applied Basic Research Foundation [2019A1515110356]
  7. China Postdoctoral Science Foundation [2019M662968]

Ask authors/readers for more resources

The nucleus is considered an ideal target for anti-tumor therapy, but there is currently a lack of nuclear-targeted drugs with good biosafety and high efficacy. In this study, a new nuclear-targeted material MeTPAE was developed, which can interact with HDACs to inhibit cell proliferation and precisely damage the nucleus through PDT. This strategy caused cell cycle arrest and exhibited excellent anti-tumor activity.
The nucleus is considered the ideal target for anti-tumor therapy because DNA and some enzymes in the nucleus are the main causes of cell canceration and malignant proliferation. However, nuclear target drugs with good biosafety and high efficiency in cancer treatment are rare. Herein, a nuclear-targeted material MeTPAE with aggregation-induced emission (AIE) characteristics was developed based on a triphenylamine structure skeleton. MeTPAE can not only interact with histone deacetylases (HDACs) to inhibit cell proliferation but also damage telomere and nucleic acids precisely through photodynamic treatment (PDT). The cocktail strategy of MeTPAE caused obvious cell cycle arrest and showed excellent PDT anti-tumor activity, which offered new opportunities for the effective treatment of malignant tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available